Stock listing
gettex:L9S Gyre Therapeutics, Inc. Aktie
German listing (gettex) of Gyre Therapeutics, Inc. · home listing NASDAQ:GYRE
Follow Gyre Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:GYRE
$4.21 USD -0.13 (-3.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:GYRE
- Day range
- $4.13 – $4.51 USDNov 20, 2026
- Volume
- 240,136 sharesNov 20, 2026
- Market cap
- $485.5M USDAt the close on Nov 20, 2026 · price × 115.3M shares outstanding
- 52-week range
- $3.97 – $9.14 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.06M USDMedian day 134,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:GYRE · Home | $4.21 USD | -0.13 (-3.0%) | 240,136 | $4.40 | $4.51 | $4.13 | $4.34 | Close on Nov 20, 2026 |
| Frankfurt:L9S | €4.08 EUR | +0.12 (+3.0%) | — | €4.08 | €4.08 | €4.08 | €3.96 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GYRE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.21 | -0.13 | -3.0% | $4.40 | $4.51 | $4.13 | 240,136 | |
| $4.34 | -0.22 | -4.8% | $4.52 | $4.718 | $4.34 | 466,591 | |
| $4.56 | +0.17 | +3.9% | $4.39 | $4.60 | $4.32 | 215,956 | |
| $4.39 | +0.08 | +1.9% | $4.47 | $4.77 | $4.35 | 577,140 | |
| $4.31 | +0.01 | +0.2% | $4.65 | $4.73 | $4.15 | 278,989 | |
| $4.30 | +0.04 | +0.9% | $4.20 | $4.36 | $4.09 | 173,993 | |
| $4.26 | +0.03 | +0.7% | $4.26 | $4.38 | $4.22 | 130,505 | |
| $4.23 | -0.42 | -9.0% | $4.63 | $4.63 | $4.215 | 141,039 | |
| $4.65 | -0.11 | -2.3% | $4.80 | $4.80 | $4.52 | 224,593 | |
| $4.76 | +0.75 | +18.7% | $4.56 | $4.79 | $4.08 | 359,700 | |
| $4.01 | -0.43 | -9.7% | $4.50 | $4.50 | $3.97 | 266,600 | |
| $4.44 | 0.00 | 0.0% | $4.57 | $4.65 | $4.33 | 256,500 | |
| $4.44 | -0.29 | -6.1% | $4.61 | $4.71 | $4.40 | 239,500 | |
| $4.73 | +0.17 | +3.7% | $4.78 | $5.11 | $4.27 | 389,800 | |
| $4.56 | -1.85 | -28.9% | $6.27 | $6.30 | $4.52 | 394,100 | |
| $6.41 | -0.68 | -9.6% | $6.86 | $6.99 | $6.37 | 185,300 | |
| $7.09 | +0.56 | +8.6% | $6.53 | $7.10 | $6.33 | 125,100 | |
| $6.53 | +0.46 | +7.6% | $6.10 | $6.55 | $6.01 | 126,400 | |
| $6.07 | +0.22 | +3.8% | $5.77 | $6.10 | $5.77 | 93,400 | |
| $5.85 | -0.01 | -0.2% | $5.85 | $5.90 | $5.70 | 151,500 | |
| $5.86 | -0.04 | -0.7% | $5.91 | $6.00 | $5.80 | 66,600 | |
| $5.90 | -0.27 | -4.4% | $6.21 | $6.21 | $5.86 | 131,400 | |
| $6.17 | +0.08 | +1.3% | $6.08 | $6.34 | $6.08 | 242,100 | |
| $6.09 | +0.01 | +0.2% | $6.10 | $6.24 | $6.05 | 119,200 | |
| $6.08 | -0.32 | -5.0% | $6.41 | $6.43 | $6.04 | 142,900 | |
| $6.40 | -0.07 | -1.1% | $6.51 | $6.65 | $6.40 | 108,800 | |
| $6.47 | -0.24 | -3.6% | $6.70 | $6.75 | $6.44 | 162,800 | |
| $6.71 | -0.16 | -2.3% | $6.89 | $6.92 | $6.71 | 85,100 | |
| $6.87 | -0.17 | -2.4% | $7.00 | $7.07 | $6.85 | 82,000 | |
| $7.04 | +0.28 | +4.1% | $6.80 | $7.09 | $6.76 | 76,600 | |
| $6.76 | -0.28 | -4.0% | $7.04 | $7.04 | $6.74 | 82,800 | |
| $7.04 | -0.04 | -0.6% | $7.03 | $7.15 | $6.99 | 99,200 | |
| $7.08 | -0.27 | -3.7% | $7.42 | $7.42 | $7.01 | 134,000 | |
| $7.35 | +0.24 | +3.4% | $7.17 | $7.43 | $7.09 | 181,500 | |
| $7.11 | +0.11 | +1.6% | $7.09 | $7.35 | $7.08 | 163,700 | |
| $7.00 | -0.33 | -4.5% | $7.35 | $7.38 | $7.00 | 140,000 | |
| $7.33 | +0.01 | +0.1% | $7.32 | $7.38 | $7.13 | 159,800 | |
| $7.32 | -0.17 | -2.3% | $7.52 | $7.74 | $7.31 | 115,100 | |
| $7.49 | +0.14 | +1.9% | $7.35 | $7.56 | $7.30 | 137,000 | |
| $7.35 | +0.02 | +0.3% | $7.39 | $7.42 | $7.13 | 134,800 | |
| $7.33 | -0.07 | -0.9% | $7.40 | $7.44 | $6.81 | 327,700 | |
| $7.40 | -0.09 | -1.2% | $7.49 | $7.50 | $7.04 | 164,500 | |
| $7.49 | +0.06 | +0.8% | $7.40 | $7.61 | $7.26 | 227,000 | |
| $7.43 | -0.12 | -1.6% | $7.55 | $7.57 | $7.21 | 364,900 | |
| $7.55 | +0.37 | +5.2% | $7.12 | $7.56 | $7.10 | 1,203,600 | |
| $7.18 | +0.48 | +7.2% | $6.80 | $7.20 | $6.80 | 143,200 | |
| $6.70 | +0.01 | +0.1% | $6.70 | $6.86 | $6.59 | 126,400 | |
| $6.69 | 0.00 | 0.0% | $6.69 | $6.72 | $6.46 | 97,800 | |
| $6.69 | -0.04 | -0.6% | $6.82 | $7.04 | $6.69 | 104,100 | |
| $6.73 | -0.01 | -0.1% | $6.86 | $6.95 | $6.73 | 69,800 | |
| $6.74 | -0.21 | -3.0% | $6.93 | $6.96 | $6.74 | 83,100 | |
| $6.95 | -0.22 | -3.1% | $7.17 | $7.27 | $6.94 | 104,700 | |
| $7.17 | +0.31 | +4.5% | $6.85 | $7.20 | $6.85 | 239,900 | |
| $6.86 | +0.42 | +6.5% | $6.44 | $6.89 | $6.41 | 56,000 | |
| $6.44 | +0.08 | +1.3% | $6.37 | $6.54 | $6.36 | 41,200 | |
| $6.36 | -0.11 | -1.7% | $6.41 | $6.67 | $6.34 | 58,100 | |
| $6.47 | -0.10 | -1.5% | $6.51 | $6.57 | $6.32 | 54,500 | |
| $6.57 | -0.02 | -0.3% | $6.60 | $6.64 | $6.43 | 41,700 | |
| $6.59 | -0.09 | -1.3% | $6.70 | $6.70 | $6.54 | 43,200 | |
| $6.68 | +0.03 | +0.5% | $6.63 | $6.77 | $6.63 | 25,300 | |
| $6.65 | -0.03 | -0.4% | $6.71 | $6.81 | $6.60 | 38,800 | |
| $6.68 | +0.24 | +3.7% | $6.53 | $6.72 | $6.49 | 44,500 | |
| $6.44 | -0.47 | -6.8% | $6.89 | $6.89 | $6.42 | 53,300 | |
| $6.91 | -0.11 | -1.6% | $7.08 | $7.12 | $6.86 | 66,000 | |
| $7.02 | -0.13 | -1.8% | $7.15 | $7.29 | $6.77 | 55,100 |
Splits
3 splits since 2015 · NASDAQ:GYRE · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-15 | Consolidation | |
| 1-for-15 | Consolidation | |
| 1-for-7 | Consolidation |
- Ticker
- gettex:L9S
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Nov 5, 2026
Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates
Latest deck · Nov 5, 2026
Investor Presentation (November 2026)
Investor deck · 25 slides
Latest news
Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates
Nov 5, 2026
Closed $4.76 (+18.7%) on Nov 6, 2026
Gyre Therapeutics to Participate in Upcoming September Investor Conferences
Sep 3, 2026
Closed $6.44 (+1.3%) on Sep 3, 2026
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
Aug 7, 2026
Closed $6.67 (+4.2%) on Aug 7, 2026
Gyre Therapeutics Appoints Three New Members to its Board of Directors
Jul 16, 2026
Closed $6.05 (-5.8%) on Jul 17, 2026
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
May 12, 2026
Closed $7.28 (-0.3%) on May 13, 2026
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
May 7, 2026
Closed $7.07 (-12.1%) on May 7, 2026
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S. and China-based Fully Integrated Biopharmaceutical Company
May 5, 2026
Closed $8.04 (+3.3%) on May 6, 2026
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
Mar 17, 2026
Closed $7.65 (+2.0%) on Mar 17, 2026
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Mar 12, 2026
Closed $7.81 (-6.2%) on Mar 12, 2026
Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
Mar 2, 2026
Closed $8.76 (+6.3%) on Mar 2, 2026
Gyre Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 12 in the last 12 months · 129 in all · newest Nov 5, 2026 · oldest 2019
- Decks
- 10 decks · latest Nov 5, 2026
Where Gyre Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:GYRE · Home listing | NASDAQ | United States | USD |
| LS Exchange:A3EE5F | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3EE5F | Lang & Schwarz | Germany | EUR |
| BOATS:GYRE | BOATS | United States | USD |
| Dusseldorf:L9S | Dusseldorf | Germany | EUR |
| Frankfurt:L9S | Frankfurt | Germany | EUR |
| Stuttgart:L9S | Stuttgart | Germany | EUR |
| Tradegate:L9S | Tradegate | Germany | EUR |
| gettex:L9S · This page | gettex | Germany | EUR |
Valuation
EV/sales 3.7× against a median of 4.1×: 5th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $428.1M USD
- P/E
- Loss
- EV/sales
- 3.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.5×
- Gross margin
- 93.9%
- Operating margin
- −13.1%
- Net margin
- −25.8%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.44
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Gyre Therapeutics, Inc. · NASDAQ:GYRE | US$485.5M | US$428.1M | n/a | 3.7× | n/a | 4.5× | −25.8% | 0.0× | 1.44 |
| Egetis Therapeutics AB · OMXSTO:EGTX | US$505.7M | US$475.4M | n/a | 73.5× | n/a | 10.7× | −613.5% | 0.1× | n/a |
| Hunan Hansen Pharmaceutical Co., Ltd. Class A · SZSE:002412 | US$498.5M | US$421.8M | 12.2× | 2.8× | n/a | 1.4× | 27.0% | 0.0× | n/a |
| Gujarat Themis Biosyn Ltd · NSE:GUJTHEM | US$495.4M | US$512.4M | 94.3× | 27.3× | 57.6× | 15.9× | 28.0% | 0.6× | n/a |
| Valneva SE · EURONEXT:VLA | US$491.9M | US$589.2M | n/a | 3.8× | n/a | 5.5× | −110.3% | 2.6× | n/a |
| Xizang Weixinkang Pharmaceutical Co., Ltd. Class A · SSE:603676 | US$484.7M | US$332.6M | 17.0× | 2.0× | n/a | 2.0× | 17.4% | 0.0× | n/a |
| Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A · SSE:603207 | US$481.5M | US$373.2M | 16.6× | 4.5× | n/a | 2.8× | 34.9% | 0.0× | n/a |
| SMS Pharmaceuticals Limited · NSE:SMSPHARMA | US$478.3M | US$478.3M | 43.3× | 4.9× | 22.7× | 5.6× | 11.4% | 0.0× | n/a |
| Aarti Drugs Limited · NSE:AARTIDRUGS | US$477.2M | US$543.0M | 19.3× | 1.8× | 13.1× | 2.6× | 8.0% | 0.4× | n/a |
| Sinotherapeutics, Inc. Class A · SSE:688247 | US$472.2M | US$350.1M | 174× | 5.9× | n/a | 2.4× | 4.5% | 0.0× | n/a |
| Zhejiang Starry Pharmaceutical Co., Ltd. Class A · SSE:603520 | US$464.6M | US$595.8M | 116× | 1.5× | n/a | 1.3× | 1.0% | 0.5× | n/a |
| Median of the others | US$483.1M | US$476.9M | 31.3× | 4.1× | 22.7× | 2.7× | 9.7% | 0.1× |
Forecasts
3 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 18.67 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.28 · 2 analysts
- Revenue, year to Dec 2026
- 112.6M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Ying Luo | Chief Executive Officer |
| Thomas Eastling | Chief Financial Officer |
| Weiguo Ye | Chief Operating Officer |
| Joshua Bergmann | General Counsel and Corporate Secretary |
| Jialiang Wang | Executive Vice President, General Manager |
| Jing Liu | Senior Vice President - Platform Chemistry |
| Leslie Robinson | Vice President - Intellectual Property and Licensing |
| Liang Zhao | VP Corporate Controller |
| Mark Marino | Senior Vice President-Clinical Development |
| Michael Plewe | Senior Vice President - Medicinal Chemistry |
| Seth Goldblum | Senior Vice President - Corporate Development |
| David Zhang | Chief Business |
| Ruoyu Chen | Chief Information Officer |
| Yue Xiong | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Ping Zhang | Chairman |
| Claire Weston | Board Member |
| Dan Weng | Board Member |
| Gordon G. Carmichael | Board Member |
| Maxwell Kirkby | Board Member |
| Renate Parry | Board Member |
| Rodney L. Nussbaum | Board Member |
| Ying Luo | Chief Executive Officer |
| Yue Xiong | Chief Scientific Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +18.7% |
| Q2 2026 | Aug 7, 2026 | +5.0% |
| Q1 2026 | May 7, 2026 · Before open | −12.1% |
| Q4 2025 | Mar 31, 2026 | +5.7% |
| Q3 2025 | Nov 7, 2025 · Before open | −1.8% |
| Q2 2025 | Aug 11, 2025 · After close | +6.9% |
| Q1 2025 | May 9, 2025 · Before open | +0.5% |
| Q4 2024 | Mar 24, 2025 · Before open | −5.2% |
| Q3 2024 | Nov 4, 2024 · After close | +1.6% |
| Q2 2024 | Aug 12, 2024 · Before open | +2.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −2.7% |
| Q4 2023 | Mar 27, 2024 | +4.1% |
| Q3 2023 | Oct 26, 2023 · After close | −1.9% |
| Q2 2023 | Aug 3, 2023 | −5.7% |
| Q1 2023 | May 4, 2023 | 0.0% |
| Q4 2022 | Mar 9, 2023 | −13.0% |
| Q3 2022 | Nov 23, 2022 | 0.0% |
| Q2 2022 | Aug 15, 2022 | −1.6% |
| Q1 2022 | May 9, 2022 | −24.5% |
| Q4 2021 | Mar 31, 2022 | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 25 slides | Nov 5, 2026 |
| Investor Presentation (September 2026) | Investor deck | 26 slides | September 2026 |
| Investor Presentation (August 2026) | Investor deck | 44 slides | Aug 26, 2026 |
| Investor Presentation (June 2026) | Investor deck | 42 slides | Jun 2, 2026 |
| Investor Presentation (May 2026) | Investor deck | 21 slides | May 14, 2026 |
| Merger or Acquisition (March 2026) | Merger or acquisition | 39 slides | Mar 2, 2026 |
| H.C. Wainwright Global Investment Conference 2025 | Conference | 18 slides | Sep 10, 2025 |
| Technical Presentation (May 2025) | Technical | 28 slides | May 22, 2025 |
| Investor Presentation (April 2025) | Investor deck | 24 slides | Apr 28, 2025 |
| Technical Presentation (September 2021) | Technical | 14 slides | Sep 9, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$23M raised · US$9 a share · Jefferies +1 Dealers: Jefferies (lead), H.C. Wainwright & Co. Use of proceeds: Advance Phase 2 trial of F351 in MASH-associated liver fibrosis in the US, R&D, manufacturing and scale-up, working capital and general corporate purposes | May 29, 2025 |
| Public offering of common stock Announced: Jefferies +1 Dealers: Jefferies (lead), H.C. Wainwright & Co. Use of proceeds: Advance Phase 2 trial of F351 in MASH-associated liver fibrosis in the US, R&D, manufacturing and scale-up, working capital and general corporate purposes | May 22, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 116.6M | 105.8M | 113.5M | 102.3M | 7.34M | 20.9M | 6.00K | 1.02M | ||
| Cost of revenue | 5.42M | 3.88M | 4.64M | 4.79M | ||||||
| Gross profit | 111.2M | 101.9M | 108.8M | 97.5M | ||||||
| Research and development | 13.7M | 12.0M | 13.8M | 16.7M | 68.9M | 53.0M | 43.9M | 21.5M | 12.8M | 11.6M |
| Operating income | 11.5M | 16.2M | -67.2M | 9.20M | -87.9M | -57.4M | -57.3M | -33.8M | -21.8M | -20.4M |
| Depreciation and amortization | 2.48M | 1.55M | 1.07M | 1.09M | 290.0K | 138.0K | 146.0K | 149.0K | 173.0K | 389.0K |
| EBITDA | 14.0M | 17.7M | -66.2M | 10.3M | -87.6M | -57.2M | -57.1M | -33.7M | -21.6M | -20.0M |
| Income before tax | 14.4M | 23.2M | -77.0M | 9.41M | -87.9M | |||||
| Income tax | 4.56M | 5.32M | 8.52M | 5.10M | ||||||
| Net income | 9.88M | 17.9M | -85.5M | 4.31M | -87.9M | -56.2M | -55.2M | -30.1M | -21.6M | -16.9M |
| Earnings per share, basic | 0.06 | 0.14 | -1.41 | 0.04 | -2.87 | -2.93 | -4.60 | -2.68 | -7.45 | -21.75 |
| Earnings per share, diluted | 0.02 | 0.05 | -1.41 | 0.03 | -2.87 | -2.93 | -4.60 | -2.68 | -7.45 | -21.75 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 49.2M | 11.8M | 33.5M | 25.2M | 44.3M | 30.4M | 15.4M | 31.2M | 14.5M | 10.3M |
| Short-term investments | 15.4M | 14.9M | 0 | 2.50M | 49.0M | 61.5M | 88.9M | 18.0M | 6.80M | |
| Receivables | 31.1M | 19.6M | 15.2M | 1.82M | 3.31M | 15.0M | ||||
| Inventory | 10.2M | 6.34M | 4.28M | 6.12M | ||||||
| Current assets | 149.4M | 64.8M | 57.2M | 49.7M | 51.5M | 89.5M | 96.1M | 124.0M | 39.1M | 37.5M |
| Property, plant and equipment | 27.5M | 23.9M | 23.3M | 17.7M | 970.0K | 433.0K | 304.0K | 386.0K | 276.0K | 444.0K |
| Total assets | 219.8M | 125.4M | 116.5M | 84.8M | 55.7M | 94.8M | 98.6M | 124.9M | 39.5M | 38.1M |
| Accounts payable | 1.33M | 108.0K | 355.0K | 122.0K | 6.42M | 5.93M | 4.28M | 1.25M | 747.0K | 837.0K |
| Current liabilities | 23.8M | 19.5M | 20.0M | 12.2M | 14.2M | 17.8M | 28.9M | 4.80M | 8.74M | 22.0M |
| Total liabilities | 31.4M | 27.0M | 38.1M | 12.5M | 14.6M | 18.8M | 30.2M | 4.97M | 8.74M | 22.0M |
| Shareholders' equity | 62.5M | 63.3M | -15.8M | 42.5M | 41.1M | 76.1M | 68.3M | 119.9M | 30.8M | 16.1M |
| Shares outstanding | 91.3M | 86.3M | 76.6M | 63.6M | 31.4M | 22.1M | 12.0M | 12.0M | 6.08M | 801.8K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.01M | -3.64M | 25.9M | 10.7M | -83.8M | -55.0M | -43.6M | -28.6M | -19.9M | -18.5M |
| Capital spending | -1.19M | -2.31M | -8.52M | -4.99M | -839.0K | -64.0K | -376.0K | -23.0K | -468.0K | |
| Free cash flow | -180.0K | -5.96M | 17.4M | 5.69M | -84.6M | -43.7M | -28.9M | -20.0M | -18.9M | |
| Cash from investing | -474.0K | -19.9M | -19.8M | -13.8M | 48.2M | 9.66M | 27.4M | -71.3M | -11.2M | -1.31M |
| Cash from financing | 24.4M | 2.10M | 2.50M | -45.0M | 49.6M | 60.4M | 327.0K | 111.3M | 21.1M | 948.0K |
| Dividends paid | -45.0M | |||||||||
| Change in cash | 25.3M | -21.7M | 8.33M | -5.03M | 14.0M | 15.0M | -15.9M | 11.5M | -10.1M | -18.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 8-K · Current report | Oct 22, 2026 | Management or board change | SEC |
| 8-K · Current report | Sep 1, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 28, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 26, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Aug 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 4, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 4, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 16, 2026 | Management or board change | SEC |
| 8-K/A · Current report, amended | Jul 15, 2026 | Results | SEC |
| S-3/A · Registration statement, amended | Jul 13, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| S-3 · Registration statement | Jun 22, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 16, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 9, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 2, 2026 | Current report | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 8-K · Current report | May 14, 2026 | Current report | SEC |
| 8-K · Current report | May 12, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 7, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | May 4, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 4, 2026 | Acquisition or disposal | SEC |
| ARS · Annual report to shareholders | Apr 27, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2026 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Apr 17, 2026 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Apr 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 23, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 13, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2026 | Current report | SEC |
| 8-K · Current report | Mar 11, 2026 | Results | SEC |
| 8-K · Current report | Mar 2, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 5, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Nov 13, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Sep 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 22, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 8-K · Current report | May 23, 2025 | Material contract | SEC |
| 424B5 · Prospectus | May 23, 2025 | Offer document | SEC |
| 424B5 · Prospectus | May 22, 2025 | Offer document | SEC |
| 8-K · Current report | May 22, 2025 | Current report | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 8-K · Current report | Apr 28, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 22, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 20, 2025 | Offer document | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 17, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 17, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 18, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 6, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 27, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Nov 27, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 20, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 20, 2024 | Other filings | SEC |
| S-3 · Registration statement | Nov 14, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13D · Big-stake notice | Sep 6, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Sep 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 8, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | Jul 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 17, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2024 | Other filings | SEC |
| RW · Request to withdraw a registration | Jul 12, 2024 | Other filings | SEC |
| RW · Request to withdraw a registration | Jul 12, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 5, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | Jul 3, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 2, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 28, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 17, 2024 | Meeting outcome | SEC |
| S-3 · Registration statement | May 30, 2024 | Offer document | SEC |
| 8-K · Current report | May 30, 2024 | Current report | SEC |
| S-3 · Registration statement | May 30, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 8-K · Current report | May 8, 2024 | Current report | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 1, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 19, 2024 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 9, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 8, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 5, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 4, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 3, 2024 | Other filings | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 2, 2024 | Other filings | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Gyre Therapeutics, Inc.’s releases · as of Nov 1, 2026
- Common shares
- 115,321,017
- Fully diluted
- 115,321,017
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 115,321,017 | Nov 1, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 1, 2026 | 115,321,017 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| M James Barrett Other companies: Senseonics Holdings, Inc. (Director · Mar 17, 2016 – May 30, 2019 · Past); Kineta Inc. (Director · Feb 10, 2016 – Jun 15, 2018 · Past); Zosano Pharma Corp (Director · Jan 26, 2015 – Jan 30, 2015 · Past); Loxo Oncology Inc (Director · Jul 31, 2014 – Jul 28, 2015 · Past); Roka Bioscience Inc (Director · Jul 16, 2014 – Jun 28, 2017 · Past); Crescent Biopharma, Inc. (Director · Jan 9, 2014 – May 18, 2018 · Past); Omthera Pharmaceuticals Inc (Director · Jul 18, 2013 – Jul 18, 2013 · Past); Supernus Pharmaceuticals, Inc. (Director · Apr 30, 2012 – Mar 16, 2016 · Past); Clovis Oncology Inc (Director · Nov 15, 2011 – Oct 11, 2018 · Past); Amicus Therapeutics Inc (Director · Jun 15, 2010 – Jun 12, 2014 · Past); Medimmune Inc (Director · Jun 30, 2006 – Jun 18, 2007 · Past); Pharmion Corp (Director · Jun 8, 2006 – Mar 7, 2008 · Past); Inhibitex Inc (Director · Feb 1, 2006 – Feb 13, 2012 · Past); Iomai Corp (Director · Jan 25, 2006 – Aug 4, 2008 · Past) | Director · Apr 11, 2006 – Jun 7, 2012 · Past |
| Ralph Snyderman Other companies: iRhythm Holdings, Inc. (Director · Since at least Jul 17, 2017); Argos Therapeutics Inc (Director · Dec 9, 2016 – Dec 31, 2016 · Past); Press Ganey Holdings Inc (Director · May 20, 2015 – Oct 21, 2016 · Past); CareDx, Inc. (Director · Jul 16, 2014 – Oct 4, 2022 · Past); Pharmaceutical Product Development Inc (Director · May 18, 2011 – Dec 5, 2011 · Past); Raptor Pharmaceutical Corp (Director · Aug 23, 2006 – Aug 23, 2006 · Past); Procter & Gamble Company (the) (Director · Feb 13, 2006 – Jun 10, 2010 · Past) | Director · Jun 13, 2007 – Jun 7, 2012 · Past |
| Errol B Desouza Other companies: Alector, Inc. (Director · Since at least Mar 19, 2024); Cyclerion Therapeutics, Inc. (Director · Apr 21, 2021 – Nov 30, 2023 · Past); Royalty Pharma plc (Director · Jun 15, 2020 – May 13, 2025 · Past); Albireo Pharma Inc (CEO, Director · Mar 29, 2010 – Sep 30, 2015 · Past); Palatin Technologies, Inc. (Director · Jul 1, 2006 – Jul 21, 2010 · Past); IDEXX Laboratories, Inc. (Director · Jan 30, 2006 – Apr 30, 2009 · Past) | Director · Apr 11, 2006 – Oct 1, 2021 · Past |
| Alan W. Dunton Other companies: CorMedix Inc. (Director · Since at least Mar 1, 2019); Palatin Technologies, Inc. (Director · Since at least Jun 22, 2011); Oragenics Inc. (Director · Since at least Apr 1, 2011); Adams Respiratory Therapeutics Inc (Director · Nov 8, 2006 – Jan 29, 2008 · Past); MediciNova, Inc. (Director · May 11, 2006 – Jun 11, 2010 · Past) | Director · Oct 18, 2006 – Aug 14, 2015 · Past |
| Augustine Lawlor Other companies: PRF Technologies Ltd. (Director · Since at least Mar 18, 2026); Cypherpunk Technologies Inc. (Chief Operating Officer · Since at least Jan 20, 2017); Globeimmune Inc (Director · Jul 1, 2014 – Mar 18, 2016 · Past); Cardiovascular Systems Inc (Director · Aug 31, 2012 – Apr 27, 2023 · Past); Human Genome Sciences Inc (Director · Oct 10, 2011 – Jul 30, 2012 · Past) | Director · Aug 20, 2015 – Aug 31, 2023 · Past |
| Alan A Musso Other companies: Research Alliance Corporation IV (Director · Since at least Jul 10, 2026); Rein Therapeutics, Inc. (Director · Since at least Oct 31, 2023); Fulcrum Therapeutics, Inc. (Chief Financial Officer · Since at least Aug 7, 2023); Bellicum Pharmaceuticals Inc (CFO and Treasurer · Dec 17, 2014 – Jul 2, 2018 · Past) | SVP, Fin+Admin, CFO & Treas · Apr 11, 2006 – Oct 17, 2014 · Past |
| Harold E. Barry Selick Other companies: Protagonist Therapeutics, Inc. (Chairman, Independent Director, Hinge Bio, Inc. · Since at least Aug 10, 2016); Molecular Templates Inc (Director · Oct 9, 2017 – Sep 27, 2024 · Past); PDL BioPharma Inc (Director · Aug 1, 2009 – Jun 20, 2019 · Past); Threshold Pharmaceuticals Inc (Chief Executive Officer, Director · Mar 14, 2006 – Mar 14, 2016 · Past) | Director · Aug 20, 2015 – Jan 16, 2018 · Past |
| Jeff Himawan Other companies: Horizon Pharma PLC (Director · Jul 28, 2011 – May 3, 2018 · Past); Iomai Corp (Director · Jan 25, 2006 – Oct 25, 2006 · Past); MediciNova, Inc. (Director · Jan 9, 2006 – Jun 14, 2011 · Past) | Director · Aug 20, 2015 – Aug 20, 2015 · Past |
| Mark B Skaletsky Other companies: Alkermes plc (Director · Sep 21, 2006 – Nov 13, 2013 · Past); ImmunoGen Inc (Director · Jul 3, 2006 – Nov 13, 2012 · Past); AMAG Pharmaceuticals Inc (Director · Feb 7, 2006 – Dec 19, 2008 · Past) | Director · Apr 11, 2006 – Jun 7, 2013 · Past |
| Sharon Tetlow Other companies: Structure Therapeutics, Inc. (Director · Since at least Feb 2, 2023); Ocera Therapeutics Inc (Acting CFO & Treasurer · Jun 11, 2014 – Jul 11, 2014 · Past); Cell Genesys Inc (SVP & CFO · Feb 7, 2006 – Oct 14, 2009 · Past) | Director · Jan 15, 2020 – Jun 9, 2021 · Past |
All 61 people
| Person | Seat |
|---|---|
| Stephen A Hill Other companies: Cellectar Biosciences, Inc. (Director · Aug 14, 2014 – Jun 24, 2020 · Past); Lipocine Inc. (Director · Jan 6, 2014 – Dec 16, 2020 · Past); ArQule Inc (President and CEO, Director · Jan 19, 2006 – Oct 4, 2007 · Past) | Director · Dec 1, 2012 – Sep 6, 2018 · Past |
| Steven Burrill Other companies: ADMA Biologics Inc (Director · Feb 13, 2012 – Feb 13, 2012 · Past); Clinical Data Inc (Director · Dec 23, 2005 – Dec 23, 2005 · Past); Depomed Inc (Director · Dec 8, 2005 – Dec 10, 2013 · Past) | Director · Aug 16, 2006 – Jul 31, 2012 · Past |
| Charles A Blixt Other companies: Lamb Weston Holdings, Inc. (Director · Nov 8, 2016 – Dec 23, 2024 · Past); Krispy Kreme Doughnuts Inc (Director · Sep 12, 2006 – Jul 27, 2016 · Past) | Director · Apr 11, 2006 – Aug 14, 2015 · Past |
| Eddie Williams Other companies: BioAtla, Inc. (Director · Since at least Dec 16, 2021); BiomX Inc. (Director · Oct 12, 2023 – Apr 14, 2025 · Past) | Director · Jan 2, 2018 – Jan 7, 2022 · Past |
| Clinton Musil Other companies: Personalis, Inc. (Chief Business Officer · Jun 19, 2019 – Mar 16, 2020 · Past) | Chief Financial Officer · Jul 1, 2020 – Feb 8, 2021 · Past |
| David M Epstein Other companies: Black Diamond Therapeutics, Inc. (SEE REMARKS, Director · Jan 29, 2020 – Jun 27, 2023 · Past) | Director · Since at least Aug 6, 2024 |
| Fletcher Payne Other companies: Aptose Biosciences Inc (Sr VP and CFO · Jun 27, 2022 – Feb 5, 2024 · Past) | Chief Financial Officer · Aug 20, 2015 – Aug 30, 2019 · Past |
| Geoffrey M D Ling Other companies: Celularity Inc. (Director · Since at least Aug 31, 2023) | Director · Jan 15, 2020 – Jan 7, 2022 · Past |
| Jeanne Y Jew Other companies: Onyx Pharmaceuticals Inc (VP, Corporate & Commercial Dev · Jan 24, 2006 – Jan 24, 2006 · Past) | Director · Sep 9, 2021 – Sep 9, 2021 · Past |
| John P Richard Other companies: Vaxart, Inc. (Director · Aug 13, 2013 – Oct 11, 2019 · Past) | Director · Apr 11, 2006 – Mar 13, 2020 · Past |
| Julia R Brown Other companies: Albireo Pharma Inc (Director · Apr 24, 2012 – Jun 7, 2018 · Past) | Director · May 12, 2010 – Aug 14, 2015 · Past |
| Nassim Usman Other companies: Principia Biopharma Inc (Director · Sep 13, 2018 – Sep 13, 2018 · Past) | Director · Aug 20, 2015 – Jun 28, 2024 · Past |
| Peter A Zorn Other companies: Albireo Pharma Inc (Chief Corp. Officer, GC & Sec · Nov 3, 2016 – Aug 21, 2017 · Past) | SVP, Lgl Affrs, GC & Secretary · Dec 19, 2007 – Jan 17, 2013 · Past |
| Seline E Miller Other companies: Rezolute, Inc. (VP Finance & CAO · Mar 4, 2019 – Mar 4, 2019 · Past) | SVP Finance; Interim CFO & PAO · Oct 13, 2021 – Aug 31, 2023 · Past |
| Veronica Cai Other companies: Valion Bio, Inc. (Chief Financial Officer · Apr 1, 2022 – Apr 1, 2022 · Past) | Controller · Aug 30, 2019 – Mar 13, 2020 · Past |
| Andrea Hunt | Director · Oct 25, 2017 – Aug 31, 2023 · Past |
| Charles C Wu | Chief Executive Officer, Director · Oct 30, 2023 – Nov 20, 2023 · Past |
| Claire Weston | Board Member · Since at least Jul 16, 2026 |
| Dan Weng | Board Member · Since at least Aug 18, 2025 |
| David A Hosford | VP, Clin Dev & Reg Affairs · Jan 23, 2014 – Jan 23, 2014 · Past |
| David Zhang | Chief Business · Since at least Jan 5, 2026 |
| Edwin Madison | Chief Scientific Officer · Aug 20, 2015 – Oct 22, 2015 · Past |
| Geoffrey C Dunbar | SVP, Clin. Dev. & Reg. Affairs · Apr 11, 2006 – Mar 29, 2011 · Past |
| Gordon G. Carmichael | Board Member · Since at least Oct 30, 2023 |
| Grant E Blouse | Chief Scientific Officer · Jul 12, 2021 – Aug 9, 2022 · Past |
| Han Ying | Chief Executive Officer, Director · Oct 30, 2023 – Aug 14, 2024 · Past |
| Howard Levy | Chief Medical Officer · Apr 18, 2016 – Aug 9, 2021 · Past |
| J Donald deBethizy | President and CEO, Director · Apr 11, 2006 – May 4, 2012 · Past |
| Jeffrey P Brennan | SVP, Bus. and Comm. Dev. & CBO · Apr 11, 2006 – Jan 17, 2013 · Past |
| Jialiang Wang | Executive Vice President, General Manager · Since at least May 4, 2026 |
| Jing Liu | Senior Vice President - Platform Chemistry · Since at least Nov 5, 2026 |
| Joshua Bergmann | General Counsel and Corporate Secretary · Since at least May 4, 2026 |
| Leslie Robinson | Vice President - Intellectual Property and Licensing · Since at least Nov 5, 2026 |
| Liang Zhao | VP Corporate Controller · Since at least Nov 5, 2026 |
| Mark Marino | Senior Vice President-Clinical Development · Since at least Nov 5, 2026 |
| Mauri K Hodges | Treasurer, CFO · May 4, 2012 – Aug 14, 2015 · Past |
| Maxwell Kirkby | Board Member · Since at least Jul 16, 2026 |
| Merouane Bencherif | SVP and Senior Scien Fellow · Apr 11, 2006 – Jan 17, 2013 · Past |
| Michael Plewe | Senior Vice President - Medicinal Chemistry · Since at least Nov 5, 2026 |
| Patrick C Rock | Secretary, GC · Aug 14, 2015 – Aug 14, 2015 · Past |
| Ping Zhang | Chairman · Since at least Jan 5, 2025 |
| Renate Parry | Director · Since at least Oct 30, 2023 |
| Rodney L. Nussbaum | Board Member · Since at least Mar 20, 2024 |
| Ruoyu Chen | Chief Information Officer · Since at least Oct 30, 2023 |
| Seth Goldblum | Senior Vice President - Corporate Development · Since at least Nov 5, 2026 |
| Steven M Toler | VP, Clin Pharm Sciences · May 31, 2012 – Oct 17, 2014 · Past |
| Thomas Eastling | Chief Financial Officer · Since at least Dec 26, 2022 |
| Weiguo Ye | Chief Operating Officer · Since at least Oct 30, 2023 |
| William S Caldwell | SVP - Drug Discovery and Dev. · Jan 9, 2009 – Sep 20, 2011 · Past |
| Ying Luo | Chief Executive Officer, Director · Since at least Dec 26, 2022 |
| Yue Xiong | Chief Scientific Officer · Since at least May 4, 2026 |
Log in to ask 6ix AI your own questions about Gyre Therapeutics, Inc.